Aperçu du projet

Spinal cord injury (SCI) is a devastating medical condition that forever changes the trajectory of life. It is also costly to the health care system, similar to traumatic brain injury or Alzheimer’s. Perhaps surprisingly, people with SCI report autonomic (i.e., automatic/unconscious) issues such as cardiovascular dysfunction as a more important health issue than walking again. One of the most common autonomic dysfunctions after SCI is extreme blood pressure (BP) instability, where BP can swing to dangerously low and high levels. BP instability is common and can occur more than 65 times/day. These BP swings can cause cognitive decline, heart attack, stroke, loss-of-consciousness and death. In fact, cardiovascular disease is up to four times more common in SCI and is the most common cause of death. The primary reason for these BP swings is inappropriate changes to autonomic nervous circuit connections after SCI. As we do not fully-understand how these connections change, we do not have effective therapies for reducing BP instability. Our study aims to reveal with unprecedented accuracy the autonomic connections (i.e., in 3D using transparent tissue, genetically-modified animal strains, optogenetic manipulations, highly-specific tracing) and characterize how they change after SCI. We recently developed a novel biointegratable device targeting autonomic connections with electrical stimulation of the spinal cord (eSTIM), which based on previous work should be able to restore normal connections and function if applied over a long-period of time. As such, we will then test if we can restore normal autonomic connections by applying long-term daily eSTIM. We expect that eSTIM targeting autonomic connections will rehabilitate function and reduce BP instability. We are the only site in the world with the necessary tools and expertise to perform this study. We patented this technology and are working with neurosurgeons to rapidly translate this into a therapy.

Impact

Spinal cord injury (SCI) often leads to a secondary problem of irregular blood pressure. That pressure problem then leads to an elevated risk of heart disease and stroke, with significant costs to the health care system in the form of medical costs, loss of productivity, and reduced quality of life. Dr. Aaron Phillips and his team developed an innovative new device that acts like a thermostat to regulate blood pressure; using implantable biotechnology, the device restores the innate system for blood pressure stability that is damaged after SCI. Dr. Phillips’ discovery is currently licensed to a publicly traded company, ONWARD Medical, which has received a breakthrough designation from the Food and Drug Administration (FDA) in the U.S. to commercialize it as a therapy for SCI, and make it available to patients. Dr. Phillips holds seven patents for his work in this area.

Chef d'équipe

Aaron Phillips , University of Calgary

Partenaire et Donateurs

The Azrieli Foundation